- Home
- EMBC vs OCS Comparison
EMBC vs OCS Comparison
Compare EMBC & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMBC
- OCS
- Stock Information
- Founded
- EMBC 1924
- OCS 2003
- Country
- EMBC United States
- OCS Switzerland
- Employees
- EMBC N/A
- OCS N/A
- Industry
- EMBC Medical/Dental Instruments
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- EMBC Health Care
- OCS Health Care
- Exchange
- EMBC Nasdaq
- OCS Nasdaq
- Market Cap
- EMBC 753.0M
- OCS 711.4M
- IPO Year
- EMBC N/A
- OCS N/A
- Fundamental
- Price
- EMBC $18.68
- OCS $22.74
- Analyst Decision
- EMBC Buy
- OCS Strong Buy
- Analyst Count
- EMBC 2
- OCS 5
- Target Price
- EMBC $19.00
- OCS $28.80
- AVG Volume (30 Days)
- EMBC 460.3K
- OCS 104.7K
- Earning Date
- EMBC 02-07-2025
- OCS 03-17-2025
- Dividend Yield
- EMBC 3.21%
- OCS N/A
- EPS Growth
- EMBC 9.84
- OCS N/A
- EPS
- EMBC 1.34
- OCS N/A
- Revenue
- EMBC $1,123,100,000.00
- OCS $1,027,571.00
- Revenue This Year
- EMBC $0.26
- OCS $6.21
- Revenue Next Year
- EMBC $1.24
- OCS $760.04
- P/E Ratio
- EMBC $13.94
- OCS N/A
- Revenue Growth
- EMBC 0.21
- OCS N/A
- 52 Week Low
- EMBC $9.93
- OCS $10.55
- 52 Week High
- EMBC $21.48
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- EMBC 42.59
- OCS 86.78
- Support Level
- EMBC $19.17
- OCS $21.80
- Resistance Level
- EMBC $20.63
- OCS $23.08
- Average True Range (ATR)
- EMBC 0.85
- OCS 0.56
- MACD
- EMBC -0.33
- OCS 0.48
- Stochastic Oscillator
- EMBC 5.03
- OCS 94.52
About EMBC Embecta Corp.
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.